[{"id":"f6e5063d-4d72-41b4-bb83-56a09d9eca4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05223036","created_at":"2022-02-05T18:29:25.061Z","updated_at":"2025-02-25T13:40:50.332Z","phase":"Phase 2","brief_title":"Testing Obeticholic Acid for Familial Adenomatous Polyposis","source_id_and_acronym":"NCT05223036","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" APC","pipe":" | ","alterations":" APC mutation","tags":["APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 01/19/2023","start_date":" 01/19/2023","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 02/21/2026","study_completion_date":" 02/21/2026","last_update_posted":"2025-02-21"},{"id":"00386017-fdba-4646-91db-e52d18a56ce7","acronym":"PEPN2011","url":"https://clinicaltrials.gov/study/NCT04851119","created_at":"2021-04-20T14:55:40.726Z","updated_at":"2024-07-02T16:35:08.278Z","phase":"Phase 1/2","brief_title":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","source_id_and_acronym":"NCT04851119 - PEPN2011","lead_sponsor":"Children's Oncology Group","biomarkers":" RNF43 • CTNNB1 • TCF7L2","pipe":" | ","alterations":" APC mutation • CTNNB1 mutation • RNF43 mutation • CTNNB1 S45P","tags":["RNF43 • CTNNB1 • TCF7L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation • CTNNB1 mutation • RNF43 mutation • CTNNB1 S45P"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 147","initiation":"Initiation: 11/08/2021","start_date":" 11/08/2021","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-04-22"},{"id":"4d7f225a-7afa-4e5a-a31b-96fb1c3ee410","acronym":"","url":"https://clinicaltrials.gov/study/NCT04195399","created_at":"2021-01-18T20:26:44.866Z","updated_at":"2024-07-02T16:35:16.137Z","phase":"Phase 2","brief_title":"A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery","source_id_and_acronym":"NCT04195399","lead_sponsor":"Children's Oncology Group","biomarkers":" CD8 • CTNNB1 • APC • CD4","pipe":" | ","alterations":" APC mutation","tags":["CD8 • CTNNB1 • APC • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ogsiveo (nirogacestat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-06"},{"id":"d1c8d534-b991-4bdd-aee5-250c8074853d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03833700","created_at":"2023-07-12T22:09:04.322Z","updated_at":"2024-07-02T16:35:16.167Z","phase":"Phase 1","brief_title":"A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)","source_id_and_acronym":"NCT03833700","lead_sponsor":"Eisai Co., Ltd.","biomarkers":" RNF43 • APC • AXIN1 • ZNRF3","pipe":" | ","alterations":" APC mutation • CTNNB1 mutation • RNF43 mutation","tags":["RNF43 • APC • AXIN1 • ZNRF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation • CTNNB1 mutation • RNF43 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E7386"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/05/2019","start_date":" 03/05/2019","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-03-06"},{"id":"2d1e326b-a843-4882-b48e-31d0ec882489","acronym":"","url":"https://clinicaltrials.gov/study/NCT06005974","created_at":"2023-08-23T16:10:48.874Z","updated_at":"2024-07-02T16:35:20.791Z","phase":"Phase 2","brief_title":"A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation","source_id_and_acronym":"NCT06005974","lead_sponsor":"Recursion Pharmaceuticals Inc.","biomarkers":" APC • RAS • AXIN1","pipe":" | ","alterations":" APC mutation","tags":["APC • RAS • AXIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e REC-4881"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/15/2024","start_date":" 01/15/2024","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-02-06"},{"id":"52833369-8f35-4158-93c0-4c396a7d8604","acronym":"GENERATE","url":"https://clinicaltrials.gov/study/NCT03762590","created_at":"2021-01-18T18:29:19.005Z","updated_at":"2024-07-02T16:35:25.717Z","phase":"","brief_title":"GENetic Education Risk Assessment and TEsting Study","source_id_and_acronym":"NCT03762590 - GENERATE","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" TP53 • BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • APC • EPCAM","pipe":" | ","alterations":" TP53 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • APC mutation • MSH2 mutation • PMS2 mutation","tags":["TP53 • BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • APC • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • APC mutation • MSH2 mutation • PMS2 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 05/08/2019","start_date":" 05/08/2019","primary_txt":" Primary completion: 12/12/2022","primary_completion_date":" 12/12/2022","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2023-12-20"},{"id":"2daa2951-8e63-44d7-b2e1-6c92b1f411c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04247503","created_at":"2021-01-18T20:38:41.861Z","updated_at":"2024-07-02T16:35:41.473Z","phase":"","brief_title":"Cohort Study of Pancreatic Cancer Risk","source_id_and_acronym":"NCT04247503","lead_sponsor":"Mayo Clinic","biomarkers":" TP53 • BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • APC • EPCAM","pipe":" | ","alterations":" TP53 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • APC mutation • MSH2 mutation • PMS2 mutation","tags":["TP53 • BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • APC • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • APC mutation • MSH2 mutation • PMS2 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 12/11/2019","start_date":" 12/11/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-01"},{"id":"1cc9042f-95f7-4074-b3ad-0d488c6c9a44","acronym":"","url":"https://clinicaltrials.gov/study/NCT01265030","created_at":"2021-01-18T05:06:26.504Z","updated_at":"2024-07-02T16:35:44.750Z","phase":"Phase 1/2","brief_title":"A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis","source_id_and_acronym":"NCT01265030","lead_sponsor":"MaineHealth","biomarkers":" APC","pipe":" | ","alterations":" APC mutation","tags":["APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 02/01/2014","start_date":" 02/01/2014","primary_txt":" Primary completion: 12/22/2021","primary_completion_date":" 12/22/2021","study_txt":" Completion: 12/22/2021","study_completion_date":" 12/22/2021","last_update_posted":"2023-06-26"},{"id":"2616fda1-27bb-45e0-aa28-222708cf4e67","acronym":"","url":"https://clinicaltrials.gov/study/NCT05014360","created_at":"2021-08-20T14:52:57.168Z","updated_at":"2024-07-02T16:35:46.607Z","phase":"Phase 1b","brief_title":"A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis","source_id_and_acronym":"NCT05014360","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" APC • STAT3","pipe":" | ","alterations":" APC mutation","tags":["APC • STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 11/10/2021","start_date":" 11/10/2021","primary_txt":" Primary completion: 02/15/2023","primary_completion_date":" 02/15/2023","study_txt":" Completion: 02/15/2023","study_completion_date":" 02/15/2023","last_update_posted":"2023-06-02"},{"id":"49e99c72-51d5-4183-a2f1-731d3050b225","acronym":"","url":"https://clinicaltrials.gov/study/NCT03333265","created_at":"2021-01-22T19:52:19.552Z","updated_at":"2024-07-02T16:36:06.572Z","phase":"Phase 2/3","brief_title":"Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride","source_id_and_acronym":"NCT03333265","lead_sponsor":"Xijing Hospital of Digestive Diseases","biomarkers":" APC","pipe":" | ","alterations":" APC mutation","tags":["APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2017","start_date":" 09/01/2017","primary_txt":" Primary completion: 08/31/2020","primary_completion_date":" 08/31/2020","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2022-07-27"},{"id":"0e9e7ed3-e36b-487a-a9d1-48ecb4915d63","acronym":"","url":"https://clinicaltrials.gov/study/NCT02961374","created_at":"2021-01-18T14:33:09.947Z","updated_at":"2024-07-02T16:36:06.664Z","phase":"Phase 2","brief_title":"Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer","source_id_and_acronym":"NCT02961374","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" APC","pipe":" | ","alterations":" APC mutation","tags":["APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 10/27/2017","start_date":" 10/27/2017","primary_txt":" Primary completion: 02/23/2020","primary_completion_date":" 02/23/2020","study_txt":" Completion: 09/27/2021","study_completion_date":" 09/27/2021","last_update_posted":"2022-07-26"},{"id":"c1812af5-f31c-4727-996c-067f0f1f8110","acronym":"","url":"https://clinicaltrials.gov/study/NCT01483144","created_at":"2021-01-18T06:11:45.479Z","updated_at":"2024-07-02T16:36:29.390Z","phase":"Phase 3","brief_title":"Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)","source_id_and_acronym":"NCT01483144","lead_sponsor":"Cancer Prevention Pharmaceuticals, Inc.","biomarkers":" APC","pipe":" | ","alterations":" APC mutation","tags":["APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Flynpovi (eflornithine/sulindac)"],"overall_status":"Completed","enrollment":" Enrollment 171","initiation":"Initiation: 10/01/2013","start_date":" 10/01/2013","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2021-06-08"},{"id":"5feb09d6-9cb4-4d6c-8cb6-8264aff097cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04678011","created_at":"2021-01-22T19:56:42.664Z","updated_at":"2024-07-02T16:36:37.081Z","phase":"","brief_title":"A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy","source_id_and_acronym":"NCT04678011","lead_sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","biomarkers":" APC","pipe":" | ","alterations":" APC mutation","tags":["APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 11/24/2020","start_date":" 11/24/2020","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2020-12-21"},{"id":"c3fdd4bb-8095-47c3-8fe6-4ff3dcb01c2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04677998","created_at":"2021-01-22T19:56:42.504Z","updated_at":"2024-07-02T16:36:37.084Z","phase":"","brief_title":"A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis","source_id_and_acronym":"NCT04677998","lead_sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","biomarkers":" APC","pipe":" | ","alterations":" APC mutation","tags":["APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 11/24/2020","start_date":" 11/24/2020","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2020-12-21"},{"id":"72775712-a31f-4bce-b25f-5e8894062042","acronym":"","url":"https://clinicaltrials.gov/study/NCT03346980","created_at":"2021-01-22T19:52:19.736Z","updated_at":"2024-07-02T16:36:50.062Z","phase":"","brief_title":"Endoscopic Evaluation of Duodenal Polyposis in Patients With Familial Adenomatous Polyposis (FAP)","source_id_and_acronym":"NCT03346980","lead_sponsor":"Copenhagen University Hospital, Hvidovre","biomarkers":" APC","pipe":" | ","alterations":" APC mutation","tags":["APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 12/01/2017","start_date":" 12/01/2017","primary_txt":" Primary completion: 01/23/2020","primary_completion_date":" 01/23/2020","study_txt":" Completion: 01/23/2020","study_completion_date":" 01/23/2020","last_update_posted":"2020-02-13"},{"id":"d99bc574-0db4-4b2b-baaf-a5198f747573","acronym":"","url":"https://clinicaltrials.gov/study/NCT03095703","created_at":"2021-01-22T19:52:19.084Z","updated_at":"2024-07-02T16:37:03.434Z","phase":"Phase 2","brief_title":"Sirolimus and Familial Adenomatous Polyposis (FAP)","source_id_and_acronym":"NCT03095703","lead_sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","biomarkers":" APC","pipe":" | ","alterations":" APC mutation","tags":["APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Completed","enrollment":" Enrollment 4","initiation":"Initiation: 10/03/2017","start_date":" 10/03/2017","primary_txt":" Primary completion: 12/10/2018","primary_completion_date":" 12/10/2018","study_txt":" Completion: 12/10/2018","study_completion_date":" 12/10/2018","last_update_posted":"2019-01-28"},{"id":"ebc320e8-5c03-4ecc-88dc-a788f595b07f","acronym":"ALCAPONE","url":"https://clinicaltrials.gov/study/NCT02281214","created_at":"2021-01-18T10:44:37.756Z","updated_at":"2024-07-02T16:37:04.244Z","phase":"","brief_title":"NGS Genome Analysis in Personalisation of Lung Cancer Treatment","source_id_and_acronym":"NCT02281214 - ALCAPONE","lead_sponsor":"Centre Georges Francois Leclerc","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • PIK3CA • AKT1 • APC","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • HER-2 mutation • ALK rearrangement • ROS1 rearrangement • APC mutation • AKT1 mutation • ALK rearrangement + PIK3CA mutation","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • PIK3CA • AKT1 • APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • HER-2 mutation • ALK rearrangement • ROS1 rearrangement • APC mutation • AKT1 mutation • ALK rearrangement + PIK3CA mutation"],"overall_status":"Completed","enrollment":" Enrollment 165","initiation":"Initiation: 10/24/2014","start_date":" 10/24/2014","primary_txt":" Primary completion: 11/17/2014","primary_completion_date":" 11/17/2014","study_txt":" Completion: 11/17/2018","study_completion_date":" 11/17/2018","last_update_posted":"2019-01-04"},{"id":"c5a5faf6-29f1-4403-86e6-6c7c8be17c12","acronym":"","url":"https://clinicaltrials.gov/study/NCT01282502","created_at":"2021-01-18T05:12:11.449Z","updated_at":"2024-07-02T16:37:04.738Z","phase":"Phase 1","brief_title":"Midostaurin (PKC412) for Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT01282502","lead_sponsor":"Massachusetts General Hospital","biomarkers":" KRAS • BRAF • PIK3CA • NRAS • PTEN","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • PIK3CA mutation • PTEN mutation • KRAS wild-type • APC mutation","tags":["KRAS • BRAF • PIK3CA • NRAS • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • PIK3CA mutation • PTEN mutation • KRAS wild-type • APC mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e midostaurin"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 08/01/2011","start_date":" 08/01/2011","primary_txt":" Primary completion: 03/01/2015","primary_completion_date":" 03/01/2015","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2018-12-12"},{"id":"4639e2af-824c-45eb-8c5b-38fa16797344","acronym":"","url":"https://clinicaltrials.gov/study/NCT00685568","created_at":"2021-01-18T02:33:46.130Z","updated_at":"2024-07-02T16:37:05.500Z","phase":"Phase 1","brief_title":"Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis","source_id_and_acronym":"NCT00685568","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" APC","pipe":" | ","alterations":" APC mutation","tags":["APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 11/21/2002","start_date":" 11/21/2002","primary_txt":" Primary completion: 04/21/2006","primary_completion_date":" 04/21/2006","study_txt":" Completion: 04/21/2006","study_completion_date":" 04/21/2006","last_update_posted":"2018-11-07"}]